Clinical trials
Full profile accessFollow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Company intelligence / Profile preview
Desert King is a global leader in the production of Quillaja saponaria and Yucca schidigera extracts, serving the pharmaceutical, food, and agricultural industries. The company is particularly renowned for its high-purity saponins, such as QS-21, which serve as critical adjuvants in modern vaccines like GSK's Shingrix and Novavax's COVID-19 vaccine. With vertically integrated operations spanning from sustainable forestry in Chile to advanced manufacturing in Mexico and the United States, Desert King provides a reliable supply chain for essential biotech components. Their expertise lies in the extraction, purification, and stabilization of natural compounds for use in human and animal health. As the world's largest producer of these extracts, they play a pivotal role in the global vaccine supply chain by maintaining rigorous GMP-compliant manufacturing standards.
Beyond the preview
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Follow clinical development from trial design and recruitment through results.
Explore licensing agreements, acquisitions, and the assets behind each deal.
Trace financing activity and the investors behind a company’s development.
Compare peer pipelines by target, modality, and therapeutic area.
Explore technology platforms and the patent landscape around relevant assets.
Connect company news and source material to the questions you’re investigating.
See how Gosset can support your research on Desert King.